Contineum Therapeutics, Inc. (CTNM) - 10-Q Summary
Business Context and Reporting Period
Company: Contineum Therapeutics, Inc.
Reporting Period: Quarter and nine months ended September 30, 2025
Business Model: Clinical-stage biopharmaceutical company developing therapies for neuroscience, inflammation, and immunology (NI&I) indications. The company has no approved products and generates no product revenue.
Key Assets: PIPE-791 (LPA1R inhibitor for IPF and chronic pain) and PIPE-307 (M1R inhibitor for depression and multiple sclerosis, partnered with J&J).
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(12,792) | $(10,267) | $(44,822) | $(27,693) |
| Operating Expenses | $14,932 | $12,974 | $50,944 | $33,847 |
| Interest Income | $1,957 | $2,741 | $6,236 | $6,377 |
| Cash & Equivalents | $42,633 | $21,943 | $42,633 | $21,943 |
| Marketable Securities | $139,774 | $182,817 | $139,774 | $182,817 |
| Total Liquidity | $182,407 | $204,760 | $182,407 | $204,760 |
| Accumulated Deficit | $(162,224) | $(102,837) | $(162,224) | $(102,837) |
Note: The filing does not provide specific margin percentages as the company has no revenue. Debt is limited to operating lease liabilities of $5.5 million.
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose 15% quarter-over-quarter (Q3 2025 vs. Q3 2024) and 50% year-over-year (9M 2025 vs. 9M 2024).
- R&D: Increased by $1.3M in Q3 and $13.4M in 9M, driven by startup costs for the PIPE-791 Phase 2 trial (IPF) and Phase 1b trials (chronic pain), and increased personnel costs.
- G&A: Increased by $0.7M in Q3 and $3.7M in 9M, primarily due to higher personnel costs and stock-based compensation.
- Capital Raising: In Q3 2025, the company sold 3.24 million shares via its At-The-Market (ATM) program, raising $19.0 million in net proceeds.
- Investment Portfolio: Marketable securities decreased by approximately $43 million from year-end 2024 to Q3 2025, reflecting maturities and sales used to fund operations.
- Interest Income: Decreased in Q3 2025 compared to Q3 2024 due to lower yields and reduced invested balances.
Guidance, Outlook, and Risks
- Clinical Milestones:
- PIPE-791: Plans to initiate a global Phase 2 trial for Idiopathic Pulmonary Fibrosis (IPF) in Q4 2025. Topline data from the chronic pain Phase 1b trial expected in H1 2026.
- PIPE-307: Phase 2 VISTA trial for Multiple Sclerosis (RRMS) fully enrolled; topline data expected in Q4 2025. J&J is recruiting for a Phase 2 trial for Major Depressive Disorder (MDD).
- Liquidity Outlook: Management believes existing cash and marketable securities ($182.4 million) are sufficient to fund operations for at least 12 months from the filing date.
- Risks:
- High uncertainty regarding clinical trial success and regulatory approval.
- Need for additional financing to sustain operations beyond the 12-month runway.
- Dependence on the J&J partnership for PIPE-307 commercialization and potential milestone payments.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $182.4 million liquidity position against the accelerating R&D spend (approx. $15M/quarter).
- PIPE-791 Phase 2 Initiation: Confirm the start date of the IPF Phase 2 trial in Q4 2025 as planned.
- PIPE-307 Data Readout: Monitor the Q4 2025 topline data release for the RRMS Phase 2 trial, which is critical for the J&J partnership value.
- ATM Program Usage: Track future sales under the $75 million ATM facility and their impact on share dilution.
- Stock-Based Compensation: Review the $23.1 million of unrecognized stock-based compensation expense expected over the next 2.7 years.